Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Haloperidol 2 mg in Healthy Volunteers (Fed)
NCT04411953Phase 1Completed
- Sponsor
- Cycle Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of haloperidol in schizophrenia (2 arms), sponsored by Cycle Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Curve from time 0 to the last measurable concentration and 1 more. Started Nov 2019; status: completed.
02
Drugs
haloperidol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04411953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411953.